Hidradenitis Suppurativa: British Journal of Dermatology State-of-the-Art Review Series

In many respects, 2024 was a good year for #HidradenitisSuppurativa (HS) and 2025 appears to be continuing in the same manner. One of the world’s top-ranking dermatology journals, the British Journal of Dermatology (BJD), has just published an #openaccess (i.e., free to everyone to read) supplement dedicated to HS (“Hidradenitis Suppurativa: BJD State-of-the-Art Reviews”; available here.

This informative and timely publication features contributions from many well-known HS specialists, as follows:

• Former BJD Editor-in-Chief and HS clinical expert Professor John Ingram sets the scene for this HS supplement in an engaging editorial piece, available here.
• Research in recent years has deepened our understanding of HS pathogenesis (i.e., the origins and development of a disease) and Professor John Frew (Sydney, Australia) provides an insightful summary of recent developments on this. This improved understanding of HS pathogenesis is leading to the identification of novel therapeutic targets and biomarkers directing therapeutic selection. “Unravelling the complex pathogenesis of hidradenitis suppurativa”, available here.
• Professor Christopher Sayed (Chapel Hill, North Carolina, USA)) and colleagues reflect on the tremendous progress in clinical trials for HS over the past couple of decades but also highlight the many remaining challenges in the design of clinical trials for HS. “An evolutionary tale on clinical trials in hidradenitis suppurativa”, available here.
• The third and final review in this series is an examination of the genetics of HS. Dr. Lynn Petukhova (New York, USA) and colleagues examine the different HS disease mechanisms that have thus far been identified from genetic studies and point toward future directions in this area. “Leveraging genotypes and phenotypes to implement precision medicine in hidradenitis suppurativa management”, available here.

Many thanks to all the contributing authors and to all involved in creating another helpful, useful, and welcome HS resource.

References [OPEN ACCESS]:

Ingram JR. Hidradenitis suppurativa: BJD state-of-the-art review series. Br J Dermatol. 2025 Feb 3;192(Supplement_1):i1-i2. doi: 10.1093/bjd/ljae455. PMID: 39895592.

Frew JW. Unravelling the complex pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2025 Feb 3;192(Supplement_1):i3-i14. doi: 10.1093/bjd/ljae238. PMID: 39895594.

Sayed CJ, Shams RB, Midgette B, Garg A. An evolutionary tale on clinical trials in hidradenitis suppurativa. Br J Dermatol. 2025 Feb 3;192(Supplement_1):i15-i21. doi: 10.1093/bjd/ljae318. PMID: 39895591.

Petukhova L, Colvin A, Koerts NDK, Horváth B. Leveraging genotypes and phenotypes to implement precision medicine in hidradenitis suppurativa management. Br J Dermatol. 2025 Feb 3;192(Supplement_1):i22-i29. doi: 10.1093/bjd/ljae399. PMID: 39895593